National Jewish Center for Immunology and Respiratory Medicine

University of Minnesota

New England Medical Center Hospitals. Inc.

Brigham Young University

National Jewish Medical and Research Center

Children's Medical Center Corporation

National Jewis Center for Immunology and Respiratory Medicine

National Jewish Center for Immunology and Respiratory

Zymogenetics, Inc.

Donald Y Leung

Patrick M Schlievert

Cody Meissner

David Fulton

Paul B Savage

Brian L Kotzin

Stanley J Szefler

Janine M Bilsborough

Jane A Gross

Raif S Geha

Joseph D Spahn

Jun Abe

The invention provides methods for decreasing or inhibiting herpesviridae (HV) infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with a herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).

Cationic steroid antimicrobial compositions and methods of use

The invention provides methods for decreasing or inhibiting poxvirus infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with poxvirus infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of poxvirus infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).

The invention relates to the isolated toxin associated with Kawasaki syndrome and the bacteria from which these are isolated.

Isolated toxin associated with Kawasaki syndrome

Disclosed is a method for diagnosing inflammation in an animal which includes analyzing cells to assess glucocorticoid receptor binding affinity or glucocorticoid receptor number. A low binding affinity and high receptor number are each indicative of inflammation. Also disclosed is a method for treating inflammation in an animal, which inflammation causes glucocorticoid receptor alteration which includes suppressing the activity or expression of cytokines which, in the absence of suppression, alter glucocorticoid receptors. Also disclosed are methods for identifying Type II glucocorticoid receptor binding abnormality and for distinguishing Type I glucocorticoid receptor binding abnormalities from Type II. Further disclosed are treatments for steroid-resistant inflammatory disorders induced by IL-2 and IL-4 which are associated with glucocorticoid receptor binding abnormalities. The treatment includes administering an agent which is an IL-2 suppressor and/or an IL-4 suppressor.

Methods of diagnosing steroid-resistant inflammation due to type I or

The invention relates to isolated nucleic acid molecules coding for toxins associated with Kawasaki Syndrome. Also described are various applications of the nucleic acid molecules.

Isolated nucleic acid molecule coding for toxin associated with Kawasaki

The invention relates to various methodologies for diagnosing Kawasaki syndrome. Various bacteria, including TSST-1 producing Staphylococcus aureus, and SPEB and SPEC producing streptococcus have been found to be indicative of the pathological condition. Also described is a Kawasaki syndrome implicated isolate of S. aureus, and therapeutic methodologies for preventing treating the condition.

Method for diagnosing kawasaki syndrome

The invention relates to various methodologies for diagnosing Kawasaki syndrome. Various bacteria, including TSST-1 producing Staphylococcus aureus, and SPEB and SPEC producing streptococcus have been found to be indicative of the pathological condition. Also described is a Kawasaki syndrome implicated isolate of S. aureus, and therapeutic methodologies for preventing treating the condition. These involve the administration of anti-TSST-1 agents which are not gamma globulin.

Method for treating Kawasaki syndrome by administration of an

The invention relates to screening of patients to determine the possible presence of Kawasaki Disease. The screening involves assaying for levels of V.beta.2 or V.beta.8.1 by immunoassay, or for the mRNA expressing either of these V.beta. elements. The polymerase chain reaction is one way the mRNA level can be determined. Once the levels in the patient are determined, they are compared to normal levels. An increase is indicative of possible Kawasaki Disease.

Method for screening for Kawasaki disease

The invention relates to a method for a steroid resistant condition via administration of gamma interferon to a subject, such as a human, afflicted with the condition. The gamma interferon is administered in an amount sufficient to alleviate at least one parameter associated with the steroid resistant condition.

Method for treating a steroid resistant condition via administration of

A method of treating patients having chronic, severe allergic disorders, such as atopic dermatitis or steroid-dependent asthma, with gamma interferon is disclosed. The method involves treating patients afflicated with atopic dermatitis or steroid-dependent asthma with effective dosages of gamma interferon, which reduces the clinical severity of their disease.

Growing community of inventors

Englewood, CO, United States of America

Donald Y Leung